Cedars-Sinai Joins Trial of COVID-19 Drug
Posted Thursday, April 2, 2020 - 6:44 pm
By Ana Figueroa
Cedars-Sinai has joined a global effort to test an experimental antiviral drug as a potential treatment for COVID-19. The institution is one of dozens taking part in the clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH). The goal is to evaluate the efficacy of remdesivir, an investigational drug developed by the biopharmaceutical company Gilead Sciences Inc., based in Foster City, California.
For full story see the print edition of The Beverly Hills Courier, or download the e-edition.